Participate in a Clinical Trial

Osteoarthritis (OA) is a chronic, degenerative condition that affects both the large and small joints in the body, and is the most common form of adult arthritis. Both the prevalence and impact of the disease are steadily increasing worldwide, thus alleviating the chronic pain associated with OA is currently a major unmet need.

CCL17 is a chemokine that has been recently identified as a peripheral mediator of inflammatory pain. GSK3858279 is a human monoclonal antibody that binds to CCL17, and prevents its expression, potentially helping to alleviate the chronic pain associated with OA.

The purpose of this Phase 2 study is to investigate the efficacy, safety, PK, TE and dose exposure-efficacy relationship of GSK3858279, and to provide the data necessary to select the optimal effective and safe dose(s) of GSK3858279 to be carried forward into Phase 3 studies in subjects with knee/hip OA.

The role of inflammation in atherosclerosis has been well established, and atherosclerosis is currently considered a hybrid disease between a metabolic disorder and chronic systemic inflammation. There is also evidence showing a link between systemic inflammation and risk of cardiovascular complications. C-reactive protein (CRP) has been shown to be a reliable measure of underlying systemic inflammation and a strong predictor of future cardiovascular events.

This study will use a cross-sectional approach and conduct testing in a large sample of patients to better understand the prevalence of systemic inflammation in patients with atherosclerotic cardiovascular disease or heart failure.

This study will assess the safety and efficacy of an E-Coli vaccine, to determine whether the vaccine will help to provide protection from urinary tract infections caused by E-Coli bacteria, and prevent the systemic bacterial infections that can occur.

Primary inclusion criteria: Adults 60+ with a history of UTI within the last 2 years.

The purpose of this study is to evaluate the efficacy and safety of Tozorakimab, in reducing symptoms and improving quality of life in patients with moderate or severe COPD who are already on optimal therapy.

Primary inclusion criteria: Adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months.

The primary purpose of this study is to assess the effect of repeated administration of ponsegromab on frequency, severity, and burden of symptoms, as well as effects on physical limitations in participants with heart failure.

Primary inclusion criteria: Adults aged 18+ with clinical evidence of heart failure, with LVEF <50% and with evidence of cachexia, fatigue, or functional impairments.

The primary purpose of this study is to assess the benefits and safety of a budesonide and formoterol fumarate inhaler on both lung function and asthma health-related quality of life.

Primary inclusion criteria: Participants aged 12-80 years, with a history of physician-diagnosed asthma >6 months, who have been regularly using a stable daily ICS or an ICS/LABA regimen.

The current study is to demonstrate the efficacy of ziltivekimab in reducing morbidity and mortality in patients with heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or HF with preserved ejection fraction (HFpEF) and systemic inflammation.

Primary inclusion criteria: Adults aged 18+ with a clinical diagnosis of heart failure (NYHA Class II-IV), and LVEF > 40%.

Contact:
613-774-2420 ext. 6211
research@wdmh.on.ca

E-Coli is a very common bacteria and is the number one cause of Urinary Tract Infections (UTIs). Left untreated, and especially in older adults, this bacteria can progress further into the internal organs and bloodstream, leading to systemic bacterial infection. Once the bacteria travels into the bloodstream and internal organs, it requires the use of complex IV antibiotics to treat. However, E-Coli bacteria is becoming highly resistant to most commonly-used antibiotics. This antibiotic resistance can lead to treatment failure, increased hospitalization, morbidity, and mortality rates, and increased healthcare costs.

This study will assess the safety and efficacy of an E-Coli vaccine, to determine whether the vaccine will help to provide protection from urinary tract infections caused by E-Coli bacteria, and prevent the systemic bacterial infections that can occur.

Primary inclusion criteria: Adults 60+ with a history of UTI within the last 2 years.